Pharmacogenetic Analysis of Voriconazole Treatment in Children

Romy Tilen 1,2,*, Paolo Paioni 1, Aljoscha N. Goetschi 3, Roland Goers 2, Isabell Seibert 2, Daniel Müller 4, Julia A. Bielicki 5, Christoph Berger 1, Stefanie D. Krämer 3 and Henriette E. Meyer zu Schwabedissen 2,*

1 Division of Infectious Diseases and Hospital Epidemiology, University Children’s Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland; paolo.paioni@kispi.uzh.ch (P.P.); christoph.berger@kispi.uzh.ch (C.B.)
2 Biopharmacy, Department of Pharmaceutical Sciences, University Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland; roland.goers@unibas.ch (R.G.); isabell.seibert@unibas.ch (I.S.)
3 Biopharmacy, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland; goetscha@student.ethz.ch (A.N.G.); stefanie.kraemer@pharma.ethz.ch (S.D.K.)
4 Institute of Clinical Chemistry, University Hospital Zurich, Rämistr. 100, 8091 Zurich, Switzerland; daniel.mueller@usz.ch
5 Paediatric Research Centre, University Children’s Hospital Basel, Basel, Spitalstrasse 33, 4056 Basel, Switzerland; juliaanna.bielicki@ukbb.ch
* Correspondence: romy.tilen@kispi.uzh.ch (R.T.); h.meyerzuschwabedissen@unibas.ch (H.E.M.z.S.)

Abstract: Voriconazole is among the first-line antifungal drugs to treat invasive fungal infections in children and known for its pronounced inter- and intraindividual pharmacokinetic variability. Polymorphisms in genes involved in the metabolism and transport of voriconazole are thought to influence serum concentrations and eventually the therapeutic outcome. To investigate the impact of these genetic variants and other covariates on voriconazole trough concentrations, we performed a retrospective data analysis, where we used medication data from 36 children suffering from invasive fungal infections treated with voriconazole. Data were extracted from clinical information systems with the new infrastructure SwissPK cdw, and linear mixed effects modelling was performed using R. Samples from 23 children were available for DNA extraction, from which 12 selected polymorphism were genotyped by real-time PCR. 192 (49.1%) of 391 trough serum concentrations measured were outside the recommended range. Voriconazole trough concentrations were influenced by polymorphisms within the metabolizing enzymes CYP2C19 and CYP3A4, and within the drug transporters ABCC2 and ABCG2, as well as by the co-medications ciprofloxacin, levetiracetam, and propranolol. In order to prescribe an optimal drug dosage, pre-emptive pharmacogenetic testing and careful consideration of co-medications in addition to therapeutic drug monitoring might improve voriconazole treatment outcome of children with invasive fungal infections.

Keywords: children; pediatric pharmacology; voriconazole; therapeutic drug monitoring; pharmacogenetics; non-linear mixed effects modelling; CYP2C19; CYP3A4; ABCC2; ABCG2

1. Introduction

Invasive fungal infection (IFI) is a serious infectious complication and a major cause of morbidity and mortality in neonates and in children with primary or acquired immunodeficiency [1]. Voriconazole is among the most important and recommended antifungal drugs to treat IFIs in children >2 years of age [2,3]. It is also prescribed (off-label) in children younger than 2 years of age although optimal dosing for this age category has not yet been established [4,5]. Voriconazole is an antifungal triazole with a broad-spectrum activity against yeasts and opportunistic molds, particularly Aspergillus spp. [6,7]. Since, invasive aspergillosis, the main indication of voriconazole in children, is associated with a high mortality rate (>50%), an efficacious and safe therapy is needed [8]. Serum trough
concentrations ($C_{\text{trough}}$) of 1 to 5.5 mg/L are considered adequate for treatment [9–12], while $C_{\text{trough}}$ of <1 mg/L were associated with increased mortality in children in some [13], but not in other studies [14]. Different studies showed improved efficacy in IFIs when voriconazole $C_{\text{trough}}$ is $\geq$ 1 mg/L [15], but the impact of supra-therapeutic voriconazole $C_{\text{trough}}$ > 5.5 mg/L and the risk for adverse reactions or toxicity remains uncertain [16–18]. Routine therapeutic drug monitoring (TDM) is strongly recommended [15,19], as targeting the narrow therapeutic window of $C_{\text{trough}}$ between 1 mg/L and 5.5 mg/L is challenged by the high inter- and intraindividual pharmacokinetic variability in children [20,21]. One cause of this variability is a saturable metabolic clearance, which leads to a dose-dependent elimination half-life and non-linear pharmacokinetics. This effect was shown in adults at regular doses (4 mg/kg q12h) and in children at higher doses (8 mg/kg q12h), the latter corresponding to the recommended maintenance dose in children from 2 to 12 years of age [22–24]. Voriconazole is metabolized in vitro by the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP3A4, while in vivo studies suggested a major role of CYP2C19 in the enzymatic conversion of voriconazole to voriconazole N-oxide [3]. The later finding with predominance of an individual metabolizing enzyme in combination with the narrow therapeutic window results in a considerable risk for drug-drug interactions. Taken together, the pharmacokinetic profile of voriconazole bears a high risk for treatment failure or toxicity. The target range of $C_{\text{trough}}$ is often not reached [25,26], even if recommended empirical maintenance doses are administered in children, according to their age and body weight (https://db.swisspeddose.ch/voriconazole, accessed on 18 November 2021).

Multiple factors affect the pharmacokinetic variability of voriconazole in pediatric patients [5]. These include the aforementioned non-linear kinetics and the potential for drug-drug interactions in addition to patient-specific characteristics such as age, body weight, liver function, and the CYP2C19 genotype. Except for CYP2C19 [27,28], only few studies have been performed in children investigating the influence of pharmacogenetics (PGx) on the pharmacokinetics of voriconazole [29,30]. One such study by Allegra et al. has recently shown that in addition to CYP2C19, single nucleotide polymorphisms (SNPs) in other genes involved in the metabolism and transport of voriconazole influence $C_{\text{trough}}$ [30]. Accordingly, it is essential to understand how genetics affect the pharmacokinetics, efficacy and safety of voriconazole in children in order to adjust drug therapy and achieve treatment success. Therefore, our aim was to investigate the impact of variants in genes potentially involved in voriconazole metabolism or transport and of typical co-medications on voriconazole $C_{\text{trough}}$ in children. Understanding the factors affecting voriconazole pharmacokinetics in children is a prerequisite towards individualized dosing schemes to eventually improve the treatment outcome in children suffering from IFIs.

2. Materials and Methods

We performed a retrospective data analysis with health-related personal data and in particular data on voriconazole medication including $C_{\text{trough}}$, information on co-medication and biological material from children with proven, probable or suspected IFI treated with voriconazole and at least one measured $C_{\text{trough}}$ between 2014 and 2019 in the University Children’s Hospitals Zurich and Basel. The study was approved by the Ethics Committee of the Kanton Zurich, Switzerland (BASEC 2020-00217).

2.1. Data Collection and TDM

Thirty-six patients treated in the two children’s hospitals matched the aforementioned inclusion criteria. Consent on use of health-related data and biological material (signed by a legal representative (parent) or by patient if older than 14 years of age) was available from all included patients. Data were extracted from the clinical and laboratory information systems of the hospitals with the recently built Swiss Personalized Health Network (SPHN) platform SwissPKcdw, a clinical data warehouse designed for the gathering and analysis of routine clinical and study related data for pharmacokinetics analyses under secure conditions [31].
Blood samples were taken immediately before drug application (C\text{trough}) under steady-state conditions. Voriconazole C\text{trough} values from the University Children’s hospital Zurich were measured in the Institute of Clinical Chemistry of the University Hospital Zurich by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) using the commercially available TDM A kit (MassTox®, Chromosystems, Munich, Germany). The laboratory of the University Hospital Basel determined the voriconazole C\text{trough} values of patients from the University Children’s Hospital Basel by a LC-MS/MS inhouse method applying turbulent-flow online extraction (Cyclone®, Thermo Fisher Scientific, Reinach, Switzerland) and reversed-phase chromatography (Synergi 4 µm Max®, Phenomenex, Basel, Switzerland) after protein precipitation of the serum samples with acetonitrile. For quantification, commercially available calibrators and controls were used (Recipe, Munich, Germany). After validation of the collected health-related data including the voriconazole C\text{trough} and required corrections based on hospital records, we performed data analysis on the SwissPKedw platform.

2.2. Genotyping

From 23 of the 36 children biological material (full blood, viable cells or DNA samples) was retrieved and pseudonymized samples were sent to the laboratory of the Biopharmacy at the Department of Pharmaceutical Sciences at the University of Basel for genetic analysis. In patients undergoing stem cell transplantation the biological material was collected prior to transplantation. Cell samples were used for DNA extraction using the QIAamp DNA Blood Mini kit and the QIAcube (Qiagen AG, Hombrechtikon, Switzerland). DNA samples were analyzed using the Tecan Infinite Pro 200 and the NanoQuantTM plate (Tecan, Maennedorf, Switzerland). Here, the concentration and 260/280-ratio was set to >5 ng/µL and 1.8–2.10, respectively, making the samples eligible for further analyses. Each DNA sample in this study reached this quality.

The DNA was used for determination of the genetic variants as listed in Table 1. For analysis commercial chemistry was used. Briefly, 5 µL TaqMan® Genotyping Master Mix were combined with 0.5 or 0.25 µL of the respective primer/probe mix (Assay) and 1 µL of the respective DNA or positive control. The final reaction volume was 10 µL, with water supplemented. For genotyping reactions with known low minor allele frequency (MAF), namely for detection of rs28399504, rs4986893, rs35599367, rs10264272, and rs776746, a heterozygous control was generated. This control was a mixture of plasmids containing the amplicon either of the reference or of the variant of the respective polymorphism. The respective genotyping polymerase chain reaction was performed and the amplicons were ligated into pDrive (Qiagen PCR cloning Kit), after amplification in E. coli, the isolated plasmids were sequenced (Microsynth, Balgach, Switzerland) and therefore verified. After combining the two plasmids, the heterozygous control was used at a concentration of 20 ng/µL in each genotyping run. We gathered the genetic variants for voriconazole based on literature and comparison with information on PharmGKB (https://www.pharmgkb.org/, accessed on 7 May 2021) [29,30,32]. The genetic panel consisted of 12 selected SNPs within the genes of metabolizing enzymes CYP2C19, CYP3A4, and CYP3A5 and of drug transporters ABCC2, ABCG2, and SLCO1B3 (Table 1).

Table 1. Summary of genetic variants determined applying commercially available TaqMan® assays (primer/probe-mixes) in this study.

| SNP-Identifier | Gene      | Genetic Variant | Assay ID   |
|----------------|-----------|-----------------|------------|
| rs2273697      | ABCC2     | c.1249G > A     | C__22272980_20 |
| rs717620       | ABCC2     | c.24C > T       | C__2814642_10  |
| rs13120400     | ABCG2     | c.1194 + 928T > C| C__9510480_10  |
| rs2231142      | ABCG2     | c.421C > A      | C__15854163_70  |
| rs12248560     | CYP2C19   | * 17; g.-806C > T| C__4698877_10  |
| rs28399504     | CYP2C19   | * 4; c.1A > G   | C__30634136_10  |
Table 1. Cont.

| SNP-Identifier | Gene      | Genetic Variant | Assay ID | *
|----------------|-----------|-----------------|---------|---
| rs4244285      | CYP2C19   | * 2; c.681G > A | C__25986767_70 |
| rs4986893      | CYP2C19   | * 3; c.636G > A | C__27861809_10 |
| rs35599367     | CYP3A4    | * 22; (intronic) C > T | C__59013445_10* |
| rs10264272     | CYP3A5    | * 6; g.14690G > A | C__30203950_10* |
| rs776746       | CYP3A5    | * 3; g.6986A > G | C__26201809_30* |
| rs4149117      | SLCO1B3   | c.334G > T      | C__25639181_40 |

Assays tagged with a * are located on the reverse strand; results were translated into coding strand prior to submitting the data to the SwissPKCDW tenant at Leonhard Med. *, indicates primer/probe-mix delivered at 40× concentration.

Following the protocol for secure data transfer previously developed, the genetic information of each individual was encrypted and transferred via the BioMedIT node SciCORE (University of Basel) to the SwissPKCDW which is hosted at the BioMedIT node Leonhard Med (ETH Zurich) [33].

2.3. Data Analysis by Linear Mixed Effects Modelling

Data were analyzed by linear mixed effects modelling with the package Lmer (v1.1-28) in the statistical computing language R (v4.0.4) [34]. Concentrations below the lower limit of quantification (LLOQ, 0.1 mg/L) were set to 0.05 mg/L. The principle model for analysis was \( \ln(C_{\text{trough}}) \sim \ln(\text{dose/body weight}) + \text{covariates} + (1|\text{ID}) \). Covariates were expressed as the difference between a logarithmic (ln) value and a logarithmic (ln) reference value as indicated, as a factor (sex, route of administration, diagnose), or as a numeric value. The numeric values for co-medication were 0 (the drug was not co-administered within the same day) and 1 (the drug was co-administered within the same day); the numeric values for variant alleles of a particular gene were 0 (reference genotype), 1 (heterozygous) or 2 (homozygous for the genetic variants). The subject’s pseudo-identity (ID) was used as the grouping factor with random intercepts. For model building, patient body weight, body surface area, body height, age, sex and secondary diagnose (IFI) as well as route of administration were evaluated as potential covariates first. The respective residues (\( \ln(\text{observed } C_{\text{trough}}) - \ln(\text{predicted } C_{\text{trough}}) \)) were plotted against co-medications and genetic variants. Co-medications and genetic variants with suspected differences in the residues were evaluated as covariates in the model. Finally, interactions were tested between drugs and genes, based on the further inspection of the residues plotted against co-medications and variant genes. Covariates were included if the respective \( p \) value for the effect (or interaction) was <0.05 and if \( -2 \times \log \text{likelihood} (\text{−2LL}) \) was significantly reduced (difference in \( \text{−2LL} > 3.84 \) for one additional degree of freedom). The model was built by alternating between addition and removal of a covariate or interaction.

3. Results

3.1. Population Description and TDM

In this analysis we included 36 pediatric patients, aged between 0.5 months and 17 years, with proven, probable or suspected IFI, and treated with voriconazole. These patients had a total of 18 different main diagnoses related to primary or acquired immunodeficiency, ranging from different types of leukemia/lymphoma and anaemia to cystic fibrosis. The characteristics of the patients are summarized in Table 2.
Table 2. Characteristics of the patient population at the beginning of voriconazole therapy.

|                        | Female | 30.6 % | Male  | 69.4 % |
|------------------------|--------|--------|-------|--------|
| Age, median (range)    | 10 (0–17) | years | N = 36 |        |
| Age, mean ± SD         | 9.6 ± 5.4 | years | N = 36 |        |
| Body weight, median (range) | 30.6 (6.5–96.9) | kg | N = 36 |        |
| Body weight, mean ± SD | 35.5 ± 21.8 | kg | N = 36 |        |
| Body surface area *, (median (range)) | 1.09 (0.33–2.25) | m² | N = 35 |        |
| Body surface area *, mean ± SD | 1.13 ± 0.49 | m² | N = 35 |        |
| Height, median (range) | 139.5 (62–188) | cm | N = 35 |        |
| Height, mean ± SD      | 133.2 ± 34.0 | cm | N = 35 |        |
| Voriconazole i.v.      | N = 21 |        |       |        |
| Voriconazole p.o.      | N = 15 |        |       |        |
| Confirmed invasive aspergillosis (IA) | N = 23 |       |       |        |
| Probable or suspected IA | N = 7 |        |       |        |
| Prophylaxis of IA      | N = 3 |        |       |        |
| Other IFI              | N = 3 |        |       |        |

* Body surface area was calculated using the Mosteller’s equation [35]. N, number of individuals.

For the 36 patients, a total number of 391 voriconazole C\text{trough} measurements, with a documented dose of the last voriconazole administration, were available. Of these, 15 measurements were below the LLOQ which was 0.1 mg/L. All children were initially treated with the clinically recommended empirical maintenance dose, followed by individual dose adjustments according to the TDM results:

- 2 to 12 years or 12 to 14 years and <50 kg: 8 mg/kg (7.5 ± 1.6 mg/kg) q12h;
- 12 to 14 years and ≥50 kg or ≥15 years: 4 mg/kg (3.6 ± 1.1 mg/kg) q12h.

Safe and effective dosing for children younger than 2 years of age has not yet been established, therefore voriconazole was prescribed off-label in 4 patients in this age group. Of the 391 measured voriconazole C\text{trough}, 192 (49.1%) were outside the recommended target C\text{trough}, range of 1–5.5 mg/L, of which 168 (87.5%) were at sub-therapeutic level, and 24 (12.5%) at supra-therapeutic level (Figure 1A). The median number of measurements per patient was 7 (range: 1 to 38). Of the 22 individuals with 6 or more available C\text{trough} measurements, 45.6% of the C\text{trough} measurements were out of the range. In 12 of these 22 individuals, >65% of the measured C\text{trough} were out of the range (Figure 1B).

We are showing the voriconazole C\text{trough} measured for all 36 patients during TDM in Figure 2A. Values below the LLOQ of 0.1 mg/L were replaced by 0.05 mg/L. As shown in Figure 2B, the C\text{trough} of the first measurement in all 36 individuals ranged from 0.1 to 9.6 mg/L with a mean ± SD of 2.189 ± 2.429 mg/L. In half of the individuals, a measurement was conducted 14 ± 2 days after the start of the therapeutic drug monitoring. Here, the observed C\text{trough} ranged from 0.1 to 7.4 mg/L, resulting in a mean ± SD of 1.844 ± 1.931 mg/L (Figure 2C).

Plotting ln(C\text{trough}) versus ln(body weight), ln(body surface area) or ln(age) revealed significant positive correlations (Figure 3), indicating that with the current dosing scheme, lighter/younger children have C\text{trough} below the recommended range more often than children with higher body weight or age, despite the higher recommended dose per body weight at the younger age and lower body weight. The significant difference between ln(C\text{trough}) of female and male patients could be related to this observation (Figure 3D); the mean body weight was 20.8 ± 15.9 kg for female patients and 39.3 ± 24.9 kg for male patients.
Figure 1. Descriptive analysis of $C_{\text{trough}}$ determined in children treated with voriconazole. (A) Results of therapeutic drug monitoring of voriconazole. (B) All voriconazole $C_{\text{trough}}$ obtained in one individual were rated for the data point being within the range of 1–5.5 mg/L (black dots, within range; red dots, outside range). Individuals without DNA available are labelled in grey. Individuals with >65% of the $C_{\text{trough}}$ out of range are highlighted by a broader circle line width.
Figure 2. (A) C\text{trough} from therapeutic drug monitoring over time of all 36 individuals. (B) First measurement and (C) one measurement per patient after 14 ± 2 days of voriconazole C\text{trough} (n = 383; 8 C\text{trough} were excluded, because they were not measured within the same therapeutic intervention period). On the logarithmic scale of the y-axis, the therapeutic window of C\text{trough} between 1 and 5.5 mg/L is highlighted in grey.
Figure 3. \(\ln(C_{\text{trough}})\) correlated with (A) \(\ln(\text{body weight})\), (B) \(\ln(\text{body surface area})\), (C) \(\ln(\text{age})\), and, (D) differed significantly between female (f) and male (m) patients. The linear regressions of the correlations in (A–C) are indicated as broken line and slope with its level of \(p\) of a two-tailed homoscedastic t-test in (D). Horizontal dotted lines indicate the recommended range for \(C_{\text{trough}}\) (1 to 5.5 mg/L). \(N\), numbers of patients with available data and included in the plot.

3.2. Genetic Analysis

For 23 of the 36 pediatric patients from the University Children’s Hospital Zurich, we were able to gather DNA samples retrospectively. The individuals were genotyped for genetic variants within drug metabolizing enzymes and drug transporters as previously suggested [29,30,32]. Analysis of the frequencies in the herein reported study population did not reveal statistically significant differences in the distribution of genotypes or MAF compared to those reported on a European population in the Allele Frequency Aggregator (ALFA) [36]. Only for the SNP rs2331142 (ABCG2) there was a tendency for a deviation in frequency (\(X^2 = 0.089\)) (Table 3).
Table 3. Summary of the genetic analysis reporting the number of individuals and the number of $C_{\text{trough}}$ measurements observed for each genotype ($n = 251$; 11 $C_{\text{trough}}$ values were excluded because of lacking information on the dose or because an additional dose was administered >2 h after the initial dose within a dosing interval). Reported is the observed MAF, and the results of the $X^2$-test.

| SNP-Identifier | Gene | Genotype: Number of Individuals/$C_{\text{trough}}$ Measurements | MAF Observed | MAF Reported * | $X^2$ a | $X^2$ b |
|----------------|------|---------------------------------------------------------------|-------------|----------------|------|------|
| rs2273697      | ABCC2| GG: 15/135 GA: 8/105 AA: 0                                  | 0.1739      | 0.2014         | 0.601| 0.610|
| rs717620       | ABCC2| CC: 12/143 CT: 10/96 TT: 1/1                                 | 0.2609      | 0.1997         | 0.830| 0.480|
| rs13120400     | ABCG2| TT: 12/140 TC: 10/83 CC: 1/17                                | 0.2609      | 0.2185         | 0.830| 0.809|
| rs2231142      | ABCG2| CC: 15/161 CA: 7/47 AA: 1/32                                | 0.1957      | 0.1026         | 0.988| 0.089|
| rs12248560     | CYP2C19| CC: 14/157 CT: 9/83 TT: 0                                   | 0.1957      | 0.2314         | 0.506| 0.515|
| rs28399504     | CYP2C19| AA: 23/240 AG: 0 GG: 0                                     | n.d.        | 0.0033         | n.a. | 0.927|
| rs4244285      | CYP2C19| GG: 16/161 GA: 6/64 AA: 1/15                                | 0.1739      | 0.1473         | 0.907| 0.762|
| rs4986893      | CYP2C19| GG: 22/224 GA: 1/16 AA: 0                                   | 0.0217      | 0.0058         | 0.994| 0.358|
| rs35599367     | CYP3A4| CC: 22/237 CT: 1/3 TT: 0                                   | 0.0217      | 0.0462         | 0.994| 0.732|
| rs10264272     | CYP3A5| GG: 23/240 GA: 0 AA: 0                                     | n.d.        | 0.0011         | n.a. | 0.975|
| rs776746       | CYP3A5| GG: 22/216 GA: 1/24 AA: 0                                   | 0.0217      | 0.0700         | 0.994| 0.435|
| rs4149117      | SLCO1B3| GG: 18/207 GT: 4/32 TT: 1/1                                 | 0.1304      | 0.1411         | 0.535| 0.563|

* ALFA Allele Frequency https://www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa, accessed on 22 March 2021; selected were the frequencies reported for the European population; a, comparing the number of individuals observed and calculated from the observed MAF; b, comparing the number of individuals observed and expected according to the ALFA MAF n.d., not detected; n.a., not applicable.

3.3. Covariate Analysis

We further analyzed the data of the 23 patients with information on genetic polymorphisms by linear mixed effects modelling to account for all potential factors influencing $C_{\text{trough}}$. Figure S1 shows the distribution of the demographic characteristics of the studied sub-population. The most simple mixed effects model with a linear relationship between $\ln(C_{\text{trough}})$ and $\ln(\text{administered dose per body weight})$ revealed the relationship $C_{\text{trough}} = 0.278 \times (\text{dose/weight})^{0.57}$, with the exponent <1 indicating that the ratio between $C_{\text{trough}}$ and the dose in mg per kg body weight is not constant. This is in agreement with the age- and body-weight dependent dosing scheme. Including body surface area or body weight as a covariate in the model significantly improved the model ($p < 0.05$ for the covariate and $-2 \log \text{LL}$ reduction by >3.84) with effects of 0.8 and 1.2, respectively, and in agreement with Figure 3. Body surface area revealed the lower $p$ and $-2 \log \text{LL}$ values in the final model and was thus included as a covariate. The addition of any further demographic parameter (body height, age, sex) or of the factors such as diagnosis or route of administration did not further improve the model.

Figures S2–S4 show the residues plotted against the demographic parameters, co-medications and genetic variants, respectively, after including dose per body weight and body surface area as covariates in the model. Including the covariate body surface area, the putative effect of the sex on $\ln(C_{\text{trough}})$ seen in Figure 3D disappeared (Figure S2), in agreement with a trend towards higher body surface area in male ($1.20 \pm 0.54 \text{ m}^2$) than in female ($0.77 \pm 0.41 \text{ m}^2$; $p = 0.065$) patients. The effects of several co-medicated drugs were tested, in particular if residues differed with $p < 0.05$ and if 3 or more patients received the co-medication. The effects of ciprofloxacin (5 patients/12 $C_{\text{trough}}$ measurements), levetiracetam (3/27) and propranolol (4/34) remained significant in the final model. All three drugs reduced $C_{\text{trough}}$ (Table 4). Plotting the remaining residues against the genotypes suggested effects on $C_{\text{trough}}$ by several of the polymorphisms (Figure S5). Effects were significant for the variant genotypes of ABCC2 rs2273697 (reducing $\ln(C_{\text{trough}})$), ABC2 rs717620 (enhancing), ABCG2 rs2231142 (enhancing), CYP2C19 rs4244285 (enhancing), CYP2C19 rs4986893 (enhancing) and CYP3A4 rs35599367 (enhancing). The remaining residues after introducing these co-medications and genes in the model are shown in Figures S5 and S6.
Table 4. Fit parameters with SE and \( p \) of the final model.

| Parameter | Reference Value for Intercept | Fit Effect | SE    | \( p \) | Significance \( a \) |
|-----------|-------------------------------|------------|-------|--------|---------------------|
| \( \theta_1 \), Intercept (\( \log(C_{trough}) \)) | | -2.0763 | 0.4637 | <10\(^{-4}\) | *** |
| \( \theta_2 \), \( \ln(\text{dose/weight, mg/kg}) \) | \( \ln(1 \text{ mg/kg}) \) | 0.8905 | 0.2004 | <10\(^{-4}\) | *** |
| \( \theta_3 \), \( \Delta \ln(\text{surface area, m}^2) \) | \( \ln(1 \text{ m}^2) \) | 1.1437 | 0.2388 | <10\(^{-5}\) | *** |
| \( \theta_4 \), ciprofloxacin | No ciprofloxacin | -0.9497 | 0.2925 | 0.0013 | ** |
| \( \theta_5 \), levetiracetam | No levetiracetam | -1.0443 | 0.2850 | 0.00051 | *** |
| \( \theta_6 \), propranolol | No propranolol | -0.5887 | 0.2671 | 0.028 | * |
| \( \theta_7 \), metamizole | No metamizole | -0.1520 | 0.1673 | 0.36 | |
| \( \theta_8 \), ABCC2 rs2273697 | ABCC2 rs2273697 GG | -0.6581 | 0.1708 | 0.00015 | *** |
| \( \theta_9 \), ABCC2 rs717620 | ABCC2 rs717620 CC | 0.4130 | 0.1918 | 0.032 | * |
| \( \theta_{10} \), ABCG2 rs2231142 | ABCG2 rs2231142 CC | 0.4481 | 0.1391 | 0.0015 | ** |
| \( \theta_{11} \), CYP2C19 rs4244285 | CYP2C19 rs4244285 GG | 0.8990 | 0.1980 | <10\(^{-5}\) | *** |
| \( \theta_{12} \), CYP2C19 rs4986893 | CYP2C19 rs4986893 GG | 1.6289 | 0.4302 | 0.00019 | *** |
| \( \theta_{13} \), CYP3A4 rs35599367 | CYP3A4 rs35599367 CC | 3.3737 | 0.6203 | <10\(^{-6}\) | *** |
| \( \theta_{14} \), metamizole \( \times \) CYP2C19 rs4244285 | No metamizole, CYP2C19 rs4244285 GG | -0.4911 | 0.2231 | 0.029 | * |

Random effects distribution (SD) and Residuals

| ID | intercept, n.a.; Residuals, 0.9385 |
|---|------------------------------------|

\( a \), \( p < 0.05; **, p < 0.005; ***; p < 0.0005; \) n.a., not applicable (see text).

Residues for the individual patient with the polymorphism CYP2C19 rs4244285 AA were in general lower if voriconazole was administered on the same day with metamizole than without this co-medication (Figure S7). In the absence of metamizole co-medication, \( C_{trough} \) of the AA genotype were in the range of those of the heterozygous carriers. Introducing the interaction term metamizole \( \times \) CYP2C19 rs4244285 in the model further improved the model with statistical significance. The residues of the final model are plotted against genotypes in Figure S8. Regarding the effects of the genetic variants, it should be noted that only one patient each carried a variant allele for CYP2C19 rs4986893 and CYP3A4 rs35599367 and that the metamizole \( \times \) CYP2C19 rs4244285 interaction was introduced in the model based on \( C_{trough} \) measurements with and without metamizole co-medication of one individual patient (carrier of the AA polymorphism).

3.4. Final Model

The final model is described in Equation (1) and Table 4. The observed \( C_{trough} \) are plotted against the simulated \( C_{trough} \) (without random effects) in Figure 4, in comparison with the model including dose/weight and body surface area only. Figure 5 shows the residues by genotype averaged per patient, before and after including co-medicated drugs and genotypes in the model. Residues with the final model plotted versus the demographic parameters and co-medications are shown in Figures S9 and S10.
\[
\log(C_{\text{trough}}) = \theta_1 + \theta_2 \times (\ln(\text{dose/weight}) - \ln(1 \text{ mg/kg})) + \theta_3 \times (\ln(\text{surface area}) - \ln(1 \text{ m}^2)) + \theta_4 \times \text{ciprofloxacin} + \theta_5 \times \text{levetiracetam} + \theta_6 \times \text{propranolol} + \theta_7 \times \text{metamizole} + \theta_8 \times \text{ABCC2 rs2273697} + \theta_9 \times \text{ABCC2 rs717620} + \theta_{10} \times \text{ABCG2 rs2231142} + \theta_{11} \times \text{CYP2C19 rs4244285} + \theta_{12} \times \text{CYP2C19 rs4986893} + \theta_{13} \times \text{CYP3A4 rs35599367} + \theta_{14} \times \text{metamizole} \times \text{CYP2C19 rs4244285} + (1|\text{ID})
\] (1)

Figure 4. Observed ln(C_{\text{trough}}) versus simulated ln(C_{\text{trough}}). (A) Before inclusion of covariates for co-medications and genetic variants in the model. (B) Final model in Table 4. Both plots, population level (no random effects included).

To further corroborate the final model, we excluded the two individual patients with the CYP2C19 rs4986893 and CYP3A4 rs35599367 variant gene, respectively. The remaining effects did not substantially change from those reported in Table 4, indicating robustness of the model (Table S1). While the random effects for the ID intercept were eliminated due to (tolerated) over-parametrization in the final model (Table 4), their distribution was fit to SD 0.342 in the model omitting the two variants with only one patient each (Table S1). The \(p\) values of the effects of propranolol, ABCC2 s717620 and the metamizole \(\times\) CYP2C19 rs4244285 interaction, however, increased to between 0.05 and 0.1. Furthermore, Table S2 shows the results without the metamizole \(\times\) CYP2C19 rs4244285 interaction effect. The difference was highest for the effect of CYP2C19 rs4244285, which was by 0.319 lower without the interaction term. Differences for all other effects were within ± 0.13. We furthermore compared the final model with a model without effects for co-medication (Table S3). The effects of the genetic polymorphisms were confirmed. As expected, they changed in effect size and \(p\) for the effects of CYP2C19 rs4244285 and ABCC2 rs2273697 increased to between 0.05 and 0.1.
Figure 5. Distribution of the residues of $\ln(C_{\text{throug}})$ (observed − predicted) according to the genotypes of the individual patients. (A) Before inclusion of covariates for co-medications and genetic variants in the model. (B) Final model in Table 4. Both plots, population level (no random effects included). Box-and-whisker plots. Individual data points are superimposed in color. Blue, CYP2C19 rs4244285 GG genotype; green, GA; red, AA. 0, homozygous reference alleles; 1, heterozygous; 2, homozygous variant alleles.

4. Discussion

In this study we analyzed the routine TDM data of 36 pediatric patients treated with voriconazole. A relevant proportion of the TDM data were out of the recommended range and this proportion remained at a comparable level over the therapy duration. Although the therapeutic window is defined, the fact that voriconazole pharmacokinetics are highly variable makes it difficult to define the appropriate dose during therapy. This high variability could also be seen in our data at the beginning and still after two weeks of treatment under TDM.

The recommended dose per body weight is higher in younger children and children with low body weight. The occurrence of sub-therapeutic $C_{\text{trough}}$ increased with decreasing body weight in our study, when plotting $\ln(C_{\text{trough}})$ versus $\ln(\text{body weight})$. A similar effect was found in the final mixed effects model which suggests that $C_{\text{trough}}$ increases with $(\text{body surface area/1 m}^2)^{1.14}$. The exponent 1.14 indicates near proportionality between $C_{\text{trough}}$ and body surface area, despite the age- and body-weight adjusted dosing scheme. Dosing schemes may thus require further adjustments, in particular for the lower age and
body weight ranges. The predicted $C_{\text{trough}}$ at the reference parameters in the final mixed effects model (body surface area, 1 m$^2$; no influencing co-medication or polymorphism, dose per body weight, 8 mg for age <12 y) was 0.80 mg/L ($\exp(\theta_1) \times (8 \text{ mg})^{\theta_2}$). It was similar (0.97 mg/L) in the model with dose per body weight and surface area as sole effects. This is in agreement with the ln($C_{\text{trough}}$) versus ln(body surface area) plot of 31 patients and is close to the recommended lower limit of therapeutic $C_{\text{trough}}$. However, the highly significant effect of body surface area in the final mixed-effects model confirmed the finding from the simple correlation: at the current dosing recommendation, predicted $C_{\text{trough}}$ are considerably lower than 1 mg/L at body surface area <1 m$^2$.

Both, the simple correlation and the mixed effects model with dose per body weight and body surface area as sole effects were not able to explain the high inter-individual and for some patients intra-individual variability in $C_{\text{trough}}$. Including the route of administration or the secondary diagnosis in the model did not improve the predictions.

In this retrospective data analysis, we focused on the influence of SNPs and co-medications in addition to the available patient-specific characteristics. We selected SNPs within CYP19 and CYP3A4 for which an association with voriconazole blood levels has been shown by other groups [29,30,37] and added SNPs of CYP3A5 as its role in the voriconazole pharmacokinetics is uncertain and further studies were requested [38].

The metabolizing enzyme CYP2C19 is the key enzyme catalyzing the formation of the inactive voriconazole N-oxide [3]. CYP2C19 is polymorph and genetic variants are known to impact voriconazole’s pharmacokinetics, so that the Clinical Pharmacogenetics Implementation Consortium (CPIC) published dosing recommendations for voriconazole treatment based on the CYP2C19 genotype for pediatric patients summarizing the evidence from the literature [27,28,32,39]. We genotyped 4 different SNPs of this enzyme. None of the patients harboured the polymorphism CYP2C19 rs28399504 (c.1A > G). Of the remaining 3 SNPs in the CYP2C19 gene, rs4244285 and rs4986893 were identified as covariates in our final model, with a significant influence on voriconazole $C_{\text{trough}}$.

CYP2C19 rs4244285 (c.681G > A) is a splicing defect variant, leads to a poor metabolizer phenotype if an individual carries two no function alleles and consequently increases trough levels [40]. Our model suggested that this polymorphism in general increased $C_{\text{trough}}$. However, the only patient who was homozygous carrying two no function alleles, had a lower median $C_{\text{trough}}$ than the median $C_{\text{trough}}$ of the 6 heterozygous patients and even of the non-carriers. The $C_{\text{trough}}$ of the rs4244285 AA carrier showed a surprisingly high intra-individual variability, though. This inspired us to search for potential interaction effects for this SNP in the model and identified metamizole co-medication as potential confounder. While it had no significant effect on $C_{\text{trough}}$ in general, its interaction with CYP2C19 rs4244285 was significant in the final model. In adult patients who are lacking CYP2C19, an increased role for CYP3A4 in the N-oxidation of voriconazole is suggested [41]. Metamizole is a weak to moderate inducer of several CYP isozymes, including CYP3A4, CYP2C9 and CYP2C19 [42]. Based on our findings, we speculate that the induction of CYP3A4 (and possibly other CYP isozymes) became relevant in the patient homozygous for the rs4244285 AA polymorphism when co-medicated with metamizole. This would explain the clustering towards higher $C_{\text{trough}}$ in the absence, and lower $C_{\text{trough}}$ in the presence of the metamizole co-medication in this individual patient. However, our hypothesis requires confirmation as it is based on one individual patient. Omission of this interaction in the final model had no major impact on the sizes of the remaining effects. Residues were similar for metamizole co-medicated and metamizole-naive heterozygous carriers of the rs4244285 polymorphism. According to the recent study [43], metamizole metabolism itself depends on the CYP2C19 genotype. We dare to speculate here that metamizole concentrations were only high enough in the homozygous CYP2C19 rs4244285 AA carrier to substantially induce CYP3A4 expression.

CYP2C19 rs4986893 (c.636G > A) is a loss-of-function mutation with predicted higher substrate concentrations as well [40]. Although we had only one patient in our population heterozygous for this variant, we considered it in the final model. The resulting $C_{\text{trough}}^*$
increasing effect was in agreement with the expectation. Omitting this polymorphism had no major impact on the final model. CYP2C19 rs12248560 g.-806C > T is associated with accelerated metabolism [40], which we could not confirm in any of our tested models, including the final model. Espinoza et al. came to a contrary conclusion in a study with immunocompromised children [44]. In their study, the averaged $C_{\text{trough}}$ was lower in carriers than non-carriers. However, as the authors discussed themselves, they did not exclude potential carriers of reduced-function CYP2C19 polymorphisms from the control group for the comparison, leaving the question unanswered whether the difference was due to the rs12248560 genotype or due to other polymorphisms in the control group (in addition). Whether the rs12248560 mutation in the promotor region results in increased CYP2C19 expression in children as observed in adults remains to be shown [45]. Our data from 9 heterozygous carriers (compared to 14 non-carriers) would not suggest that.

The CYP3A4 rs35599367 C > T in intron 6 occurs with a frequency of 5–7% in the Caucasian population and carriers are assumed to have lower hepatic CYP3A4 expression and activity [46]. In our population, only one patient carried the CT variant. This child had also a loss of function mutation in CYP2C19 rs4244285 (GA genotype). Extremely high $C_{\text{trough}}$ (up to 24.6 mg/L) were measured, even after reducing the dose and the therapy had to be discontinued due to neurotoxicity. We included the polymorphism in our final model although it was represented by only one patient. Excluding it from the final model had no major impact on the remaining effects. No influence on voriconazole $C_{\text{trough}}$ was found for the genetic variant CYP3A5 rs776746 (g.6986A > G) and none of the patients harboured the variant CYP3A5 rs10264272 (g.14690G > A).

In addition to the voriconazole metabolizing enzymes our selection of genetic variants included genes encoding for drug transporters $ABCC2$, $ABCG2$, and $SLCO1B3$ with a known or suspected role in voriconazole pharmacokinetics [30,47].

The ATP binding cassette (ABC) transporter multidrug resistance-associated protein 2 (MRP2) encoded by the $ABCC2$ gene is expressed on the apical membranes of the intestinal epithelia, the kidney proximal tubules, and the canalicular membrane of hepatocytes, where it governs biliary excretion of its substrates [48]. In vitro data do not support that voriconazole interacts with MRP2 [49]. However, Zeng et al. observed an influence of the genetic variant $ABCC2$ rs2273697 (c.1249G > A), that increases the activity of the transporter [50], on voriconazole concentrations in patients undergoing hematopoietic stem cell transplantation [47]. We confirmed this effect in our study which included 8 heterozygous pediatric patients; the $ABCC2$ rs2273697 polymorphism had a significant negative effect on $C_{\text{trough}}$ in the final model. The influence of MRP2 on voriconazole pharmacokinetics is further substantiated by our study as we also confirmed that the variant $ABCC2$ rs717620 (c.-24C > T), which is associated with lower expression levels of MRP2 [51], has an $C_{\text{trough}}$ increasing effect as previously described by Allegra et al. directly comparing carriers and non-carriers in a Student’s t-test [30]. The rs717620 polymorphism is also known for its association with methotrexate toxicity in childhood acute lymphoblastic leukemia [52]. Our results for the two SNPs rs2273697 and rs717620 in the $ABCC2$ gene support its influence on voriconazole $C_{\text{trough}}$. However, it remains to be tested whether voriconazole is indeed a substrate of the MRP2 transporter in vivo.

The breast cancer resistance protein (BCRP) is a drug transporter encoded by the $ABCG2$ gene and is expressed in the sinusoidal membrane of hepatocytes where it affects plasma clearance through hepatobiliary elimination, and in the apical membrane of enterocytes where it limits oral bioavailability through intestinal elimination [53]. Over-expression of BCRP in cancer cells is associated with high levels of resistance to various anticancer drugs [54]. There are no in vitro data supporting interaction of voriconazole with BCRP [49,55]. Nevertheless, we included two different genetic variants of ABCG2 in the genetic testing, as Allegra et al. had reported that ABCG2 rs13120400 (c.1194 + 928T > C), although it does not belong to the major ABCG2 genetic variants of known clinical relevance [56], had an influence on voriconazole $C_{\text{trough}}$, and values were increased in children carrying the ABCG2 rs13120400 CC genotype. While the rs13120400 polymorphism had no
significant effect in our study, the ABCG2 rs2231142 (c.421C > A) missense mutation, which is suggested to reduce level and function of BCRP [56], significantly increased voriconazole C\textsubscript{trough} in 7 heterozygous and 1 homozygous patient. Our study adds evidence that besides MRP2 (ABCC2) also BCRP (ABCG2) is involved in voriconazole pharmacokinetics.

In addition to the members of the ABC-transporter family, our selection also included a genetic variant located within the gene encoding for the hepatic uptake transporter OATP1B3 [57]. Allegra et al. reported that the genetic variant SLCO1B3 rs4149117 (c.334G > T) is associated with significantly reduced C\textsubscript{trough} values in 4 carriers either hetero- or homozygous for the variant allele. Our study including 4 heterozygous and 1 homozygous carriers did not confirm this effect.

While we found ample agreement between our study and published results regarding the effects of genetic polymorphisms, the identified effects of co-medications in our study were entirely unexpected. Ciprofloxacin, levetiracetam and propranolol had each a significant reducing effect on voriconazole C\textsubscript{trough}. The strength of the effects was in the range of that of the genetic polymorphisms. The three drugs have a relatively high dose in common, favoring drug-drug interactions of any kind. Possible mechanisms involved in drug-related concentration reduction are (i) the induction of enzyme or transporter expression, (ii) the increase in blood flow in the eliminating organ and (iii) the competition for plasma-protein binding. All three mechanisms may increase a co-medicated drug’s clearance and point iii may result in lower serum concentrations due to an increase in volume of distribution [26]. Voriconazole is a low-extraction drug (clearance << organ plasma flow) [24]; an increase in organ blood flow would, therefore, not affect its pharmacokinetics substantially, excluding this as a probable mechanism. Ciprofloxacin is an inhibitor of CYP isozymes [58], but not known as an enzyme or transporter inducer and plasma protein binding is considered irrelevant regarding drug-drug interactions [59]. For levetiracetam, the available in vitro reports on its CYP-inducing effects are controversial [60,61]. Nevertheless, in clinical use, levetiracetam is considered to be a non-enzyme-inducing antiepileptic drug for which CYP enzymes play a minor role in elimination [62–64]. However, its pharmacokinetics appear to be influenced by the co-administration of CYP-inducers (enzyme inducing AEDs) [65]; the underlying mechanisms require further investigation. Propranolol is a substrate of several CYP isozymes [58], but not known as an inducer of CYPs or transporter proteins. Drug-drug interactions with propranolol based on competitive plasma protein binding are not known. We searched our data for potential effects of combinations of ciprofloxacin, levetiracetam or propranolol with other drugs, but did not find any. Searching the literature did not reveal any known drug-drug interactions between voriconazole and the three drugs. Factors related to these co-medications, such as their indications, may have resulted in their significant effects in the mixed-effects model. However, the indications for these drugs were not always available from the extracted data.

All significant effects in the model were above 0.41 (below −0.58, respectively). This corresponds to increases in C\textsubscript{trough} of 50% or more (>exp(0.41)) and reductions by 44% or more. We, therefore, consider all identified effects as potentially clinically relevant. The C\textsubscript{trough}-increasing effects were highest for body surface area (proportional) and CYP2C19 rs4244285 polymorphism (C\textsubscript{trough} 2.5-fold higher). The C\textsubscript{trough}-reducing effects were strongest for levetiracetam and ciprofloxacin co-medications, both reducing C\textsubscript{trough} to 35–40% of controls, followed by the ABCC2 rs2273697 polymorphism, reducing C\textsubscript{trough} to ~50% of the controls. These estimates are for the heterozygous carriers. The effects of the polymorphisms with only one carrier were not included in this ranking. Based on these findings, we recommend adjusting the current dosing scheme to achieve higher C\textsubscript{trough} in children with body surface area <1 m\textsuperscript{2}. However, a prospective study needs to show whether this is better achieved by increasing the dose or by reducing the dosing interval. The first approach may result in toxic peak levels, the latter in drug accumulation. The right choice can only be made based on the voriconazole pharmacokinetics in this sub-group of pediatric patients, i.e., based on more concentration measurements between drug administrations. We furthermore recommend to genotype for CYP2C19 rs4244285
and potentially ABCC2 rs2273697. As both polymorphisms affect the elimination, adjusting the dosing interval may be more sensible than adjusting the dose. The CYP2C19 rs4244285 polymorphism would require prolongation, the ABCC2 rs2273697 polymorphism reduction of the dosing interval. As the strong effects of the co-medicated ciprofloxacin, levetiracetam and propranolol where unexpected, we highly suggest to closely monitor voriconazole $C_{\text{trough}}$ in combination with these drugs and adjust dosing schemes accordingly.

Our study was retrospective, and a limited number of patients were included. Some of the identified effects were based on <3 patients. To exclude any bias from these effects, the final model was confirmed after excluding these effects/patients. The high number of co-medicated drugs in these patients rendered the analysis of effects from co-medicated drugs challenging. The unexpected findings for co-medications in our model need thus to be interpreted with care.

5. Conclusions

Our results suggest that children with body surface area <1 $m^2$ are at highest risk for $C_{\text{trough}}$ below the recommended 1 mg/L. Our study confirmed the well accepted effect of the CYP2C19 genotype on voriconazole serum concentrations. It furthermore suggests effects on the concentrations by polymorphisms in the ABCC2 and ABCG2 transporters. Further effects by polymorphic CYP3A4 and co-medication with ciprofloxacin, levetiracetam and propranolol, as well as a CYP2C19-genotype dependent metamizole effect need to be confirmed. Our study provides evidence that the high inter- and intraindividual variability in voriconazole serum concentrations are predictable and that, therefore, prospective pharmacokinetics studies will allow the refinement of the dosing recommendations for seriously ill children. For the prescription of an optimal drug dosing scheme, in addition to therapeutic drug monitoring pre-emptive PGx testing for CYP2C19 is recommended and potentially genotyping for ABCC2 could in the future play a significant role in clinical routine. Attention should also be paid to a careful selection of co-medications in patients suffering from IFI and treated with voriconazole.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics14061289/s1, Figure S1: Demographic characteristics of the sub-population with information on genetic polymorphisms, analyzed by linear mixed effects modelling; Figure S2: Residues (observed ln($C_{\text{trough}}$) minus simulated ln($C_{\text{trough}}$)) plotted against demographic parameters as indicated after including dose per body weight and body surface area as covariates in the model; Figure S3: Residues plotted against co-medication as indicated after including dose per body weight and body surface area as covariates in the model; Figure S4: Residues plotted against gene variants as indicated after including dose per body weight and body surface area as covariates in the model; Figure S5: Residues plotted as in Supplementary Figure S4, but including co-medication with ciprofloxacin, levetiracetam and propranolol as covariates; Figure S6: As Supplementary Figure S5, but in addition including the significant effects of the genetic variants in the model; Figure S7: Residues shown in Figure S6 plotted versus the CYP2C19 rs4244285 genotype; Figure S8: As Supplementary Figure S6, but for the final model, including the interaction term metamizole $\times$ CYP2C19 rs4244285 in the model; Figure S9: Residues from the final model plotted versus demographic parameters; Figure S10: Residues from the final model plotted versus co-medication. Colors, as in Supplementary Figure S3; Table S1: Final model after exclusion of the two carriers of a CYP2C19 rs49868693 or CYP3A4 rs35599367 variant gene; Table S2: Final model, but without the metamizole $\times$ CYP2C19 rs4244285 interaction; Table S3: Final model, but without effects for co-medication.

Author Contributions: Conceptualization, R.T. and H.E.M.z.S.; data provision, R.T. and J.A.B.; methodology, R.T., A.N.G., D.M., S.D.K. and H.E.M.z.S.; investigation, R.T., I.S. and S.D.K.; writing—original draft preparation, R.T., H.E.M.z.S., C.B. and S.D.K.; writing—review and editing, all authors; visualization, R.T., H.E.M.z.S. and S.D.K.; supervision, H.E.M.z.S., C.B. and S.D.K.; SwissPKcdw, R.G. and P.P.; All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Swiss Personalized Health Network: 2018DEV21, infrastructure development project SwissPKcdw.
Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Kanton Zurich, Switzerland (BASEC 2020-00217).

Informed Consent Statement: General consent was obtained from all subjects involved in the study (signed by a legal representative (parent) or by patient if older than 14 years of age).

Data Availability Statement: Secure access to the data presented in this study is available on request according to the data sharing policies of SPHN. The data are not publicly available due to confidentiality reasons.

Acknowledgments: Katharina Rentsch (Department of Clinical chemistry, University Hospital Basel) for review and editing their TDM method. Beat Bangerter (IT department, University Children’s Hospital Zurich) and Vera Jäggi (Data manager, SwissPKc dw) for technical support. Irina Banzola (Management and Lab manager, SPHO Biobank Network) for providing viable cell samples. Linda Stamm (Study nurse, Paediatric Research Centre, University Children’s Hospital Basel) for data validation.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Lehrnbecher, T.; Groll, A.H. Invasive fungal infections in the pediatric population. Expert Rev. Anti-Infect. Ther. 2011, 9, 275–278. [CrossRef]
2. Warris, A.; Lehrnbecher, T.; Rolides, E.; Castagnola, E.; Bruggemann, R.J.M.; Groll, A.H. Ecmd-ecmm guideline: Diagnosis and management of invasive aspergillosis in neonates and children. Clin. Microbiol. Infect. 2019, 25, 1096–1113. [CrossRef]
3. Fischer. Vfend® Summary of Product Characteristics. Available online: https://www.ema.europa.eu/en/documents/product-information/vfend-epar-product-information_en.pdf (accessed on 7 January 2020).
4. Shima, H.; Miharu, M.; Osumi, T.; Takahashi, T.; Shimada, H. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr. Blood Cancer 2010, 54, 1050–1052. [CrossRef]
5. Kadam, R.S.; Van Den Anker, J.N. Pediatric clinical pharmacology of voriconazole: Role of pharmacokinetic/pharmacodynamic modeling in pharmacotherapy. Clin. Pharmacokinet. 2016, 55, 1031–1043. [CrossRef]
6. Herbrecht, R. Voriconazole: Therapeutic review of a new azole antifungal. Expert Rev. Anti-Infect. Ther. 2004, 2, 485–497. [CrossRef]
7. Theuretzbacher, U.; Ihle, F.; Derendorf, H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 2006, 45, 649–663. [CrossRef]
8. Steinbach, W.J. Invasive aspergillosis in pediatric patients. Curr. Med. Res. Opin. 2010, 26, 1779–1787. [CrossRef]
9. Pascual, A.; Calandra, T.; Bolay, S.; Buclin, T.; Bille, J.; Marchetti, O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 2008, 46, 201–211. [CrossRef]
10. Karthaus, M.; Lehrnbecher, T.; Lipp, H.P.; Kluge, S.; Buchheidt, D. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients—An evidence-based approach. Ann. Hematol. 2015, 94, 547–556. [CrossRef]
11. Park, W.B.; Kim, N.H.; Kim, K.H.; Lee, S.H.; Nam, W.S.; Yoon, S.H.; Song, K.H.; Choe, P.G.; Kim, N.J.; Jang, I.J.; et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: A randomized controlled trial. Clin. Infect. Dis. 2012, 55, 1080–1087. [CrossRef]
12. Ashbee, H.R.; Barnes, R.A.; Johnson, E.M.; Richardson, M.D.; Gorton, R.; Hope, W.W. Therapeutic drug monitoring (tdm) of antifungal agents: Guidelines from the british society for medical mycology. J. Antimicrob. Chemother. 2014, 69, 1162–1176. [CrossRef] [PubMed]
13. Neely, M.; Rushing, T.; Kovacs, A.; Jelliffe, R.; Hoffman, J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 2010, 50, 27–36. [CrossRef] [PubMed]
14. Hanai, Y.; Hamada, Y.; Kimura, T.; Matsumoto, K.; Takahashi, Y.; Fujii, S.; Nishizawa, K.; Takesue, Y. Optimal trough concentration of voriconazole therapeutic drug monitoring in children: A systematic review and meta-analysis. J. Infect. Chemother. 2021, 27, 151–160. [CrossRef] [PubMed]
15. Luong, M.L.; Al-Dabbagh, M.; Groll, A.H.; Racil, Z.; Nannya, Y.; Mitsani, D.; Husain, S. Utility of voriconazole therapeutic drug monitoring: A meta-analysis. J. Antimicrob. Chemother. 2016, 71, 1786–1799. [CrossRef]
16. Soler-Palacin, P.; Frick, M.A.; Martin-Naldà, A.; Lasnà, M.; Pou, L.; Rosello, E.; de Heredia, C.D.; Figueras, C. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: A prospective study. J. Antimicrob. Chemother. 2012, 67, 700–706. [CrossRef]
17. Silva, F.; Navea, D.; Saias, C.; Torres, J.P.; Catalàn, P.; Morales, J. [Analysis of voriconazole serum concentrations and safety profile in pediatric oncology patients]. Rev. Chil. Infectol. 2016, 33, 127–134. [CrossRef]
18. Troke, P.F.; Hockey, H.P.; Hope, W.W. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob. Agents Chemother. 2011, 55, 4782–4788. [CrossRef]
19. Goers, R.; Coman Schmid, D.; Jäggi, V.F.; Paioni, P.; Okoniewski, M.J.; Parker, A.; Bangerter, B.; Georgakopoulou, S.; Sengstag, T.; N. Engl. J. Med. 2016, 375, 1289–1299.

20. Tucker, L.; Higgins, T.; Engelund, E.F.; Zou, B.; Vijayan, V.; Peloquin, C.A. Voriconazole monitoring in children with invasive fungal infections. J. Pediatr. Pharmacol. Ther. 2015, 20, 17–23. [CrossRef]

21. Boast, A.; Curtis, N.; Cranswick, N.; Gwee, A. Voriconazole dosing and therapeutic drug monitoring in children: Experience from a paediatric tertiary care centre. J. Antimicrob. Chemother. 2016, 71, 2031–2036. [CrossRef]

22. Karlsson, M.O.; Lutsar, I.; Milligan, P.A. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 2009, 53, 935–944. [CrossRef] [PubMed]

23. Walsh, T.J.; Driscoll, T.; Milligan, P.A.; Wood, N.D.; Schlamm, H.; Groll, A.H.; Jafri, H.; Arrieta, A.C.; Klein, N.J.; Lutsar, I. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob. Agents Chemother. 2010, 54, 4116–4123. [CrossRef] [PubMed]

24. Michael, C.; Bierbach, U.; Frenzel, K.; Lange, T.; Basara, N.; Niederwieser, D.; Mauz-Korholz, C.; Preiss, R. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob. Agents Chemother. 2010, 54, 3225–3232. [CrossRef] [PubMed]

25. Bartelink, I.H.; Wolfs, T.; Jonker, M.; de Waal, M.; Egberts, T.C.; Ververs, T.T.; Boelens, J.J.; Bierings, M. Highly variable plasma concentrations of voriconazole in paediatric hematopoietic stem cell transplantation patients. Antimicrob. Agents Chemother. 2013, 57, 235–240. [CrossRef]

26. Liu, L.; Zhou, X.; Wu, T.; Jiang, H.; Yang, S.; Zhang, Y. Dose optimisation of voriconazole with therapeutic drug monitoring in children: A single-centre experience in China. Int. J. Antimicrob. Agents 2017, 49, 483–487. [CrossRef]

27. Narita, A.; Muramatsu, H.; Sakaguchi, H.; Doisaki, S.; Tanaka, M.; Hama, A.; Shimada, A.; Takahashi, Y.; Yoshida, N.; Matsumoto, K.; et al. Correlation of cyp2c19 phenotype with voriconazole plasma concentration in children. J. Pediatr. Hematol. Oncol. 2013, 35, e219–e223. [CrossRef]

28. Hicks, J.K.; Crews, K.R.; Flynn, P.; Haidar, C.E.; Daniels, C.C.; Yang, W.; Panetta, J.C.; Pei, D.; Scott, J.R.; Molinelli, A.R.; et al. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by cyp2c19 diplotype. Pharmacogenomics 2014, 15, 1065–1078. [CrossRef]

29. Chuwongwattana, S.; Jantararoungtong, T.; Prommas, S.; Medhasi, S.; Puangpetch, A.; Sukasem, C. Impact of cyp2c19, cyp3a4, and fmo3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections. Pharmacol. Res. Perspect. 2020, 8, e00665. [CrossRef]

30. Allegra, S.; Fatiguso, G.; Francia, S.; Pirro, E.; Carcieri, C.; Cusato, J.; Nicolo, A.; Avataneo, V.; Perri, G.D.; d’Avolio, A. Pharmacogenetic of voriconazole antifungal agent in pediatric patients. Pharmacogenomics 2018, 19, 913–925. [CrossRef]

31. Goers, R.; Coman Schmid, D.; Jäggi, V.E.; Paioni, P.; Okoniewski, M.J.; Parker, A.; Bangert, B.; Georgakopoulou, S.; Sengstag, T.; Bielicki, J.; et al. SwissP(k)(cdw)—A clinical data warehouse for the optimization of pediatric dosing regimens. CPT Pharmacomet. Syst. Pharmacol. 2021, 10, 1578–1587. [CrossRef]

32. Moriyama, B.; Obeng, A.O.; Barbarino, J.; Penzak, S.R.; Henning, S.A.; Scott, S.A.; Agüéndez, J.; Wingard, J.R.; McLeod, H.L.; Klein, T.E.; et al. Clinical pharmacogenetics implementation consortium (cpc) guidelines for cyp2c19 and voriconazole therapy. Clin. Pharmacol. Ther. 2017, 102, 45–51. [CrossRef] [PubMed]

33. Coman Schmid, D.; Crameri, K.; Oesterle, S.; Rinn, B.; Sengstag, T.; Stockinger, H. Sphn—the biomedit network: A secure IT platform for research with sensitive human data. In Digital Personalized Health and Medicine, Proceedings of the 30th Medical Informatics Europe Conference (MIE 2020) (Cancelled), Geneva, Switzerland, 28 April–1 May 2020; Pape-Haugaard, L.B., Lovis, C., Cort Madsen, I., Weber, P., Hostrup Nielsen, P., Scott, P., Eds.; IOS Press: Amsterdam, The Netherlands, 2020; Volume 270, pp. 45–51. [CrossRef] [PubMed]

34. Scott, S.A.; Sangkuhl, K.; Shuldiner, A.R.; Hulot, J.S.; Thorn, C.F.; Allman, R.B.; Klein, T.E. Pharmgkb summary: Very important pharmacogenome for cytochrome p450, family 2, subfamily c, polypeptide 19. Pharmacogenet. Genom. 2012, 22, 159–165. [CrossRef]
41. Hyland, R.; Jones, B.C.; Smith, D.A. Identification of the cytochrome p450 enzymes involved in the n-oxidation of voriconazole. Drug Metab. Dispos. 2003, 31, 540–547. [CrossRef]

42. Bachmann, F.; Duthaler, U.; Meyer Zu Schwabedissen, H.E.; Puchkov, M.; Huwyler, J.; Haschke, M.; Krähenbühl, S. Metamizole is a moderate cytochrome p450 inducer via the constitutive androstane receptor and a weak inhibitor of cyp1a2. Clin. Pharmacol. Ther. 2021, 109, 1505–1516. [CrossRef]

43. Bachmann, F.; Meyer Zu Schwabedissen, H.E.; Duthaler, U.; Krähenbühl, S. Cytochrome p450 1a2 is the most important enzyme for hepatic metabolism of the metamizole metabolite 4-methylaminoantipyrine. Br. J. Clin. Pharmacol. 2022, 88, 1885–1896. [CrossRef]

44. Espinoza, N.; Galdames, J.; Navea, D.; Farfán, M.J.; Salas, C. Frequency of the cyp2c19*17 polymorphism in a chilean population and its effect on voriconazole plasma concentrations in immunocompromised children. Sci. Rep. 2019, 9, 8863. [CrossRef]

45. Zanger, U.M.; Schwab, M. Cytochrome p450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 2013, 138, 103–141. [CrossRef] [PubMed]

46. Elens, L.; van Gelder, T.; Hesselink, D.A.; van Schaik, R.H. Cyp3a4*22: Promising newly identified cyp3a4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 2013, 14, 47–62. [CrossRef] [PubMed]

47. Zeng, G.; Shi, L.; Li, H.; Wang, L.; Zhu, M.; Luo, J.; Zhang, Z. Effect of cyclosporine a and polymorphisms in cyp2c19 and abcc2 on the concentration of voriconazole in patients undergoing allogeneic hematopoietic stem cell transplantation. Xenobiotica 2020, 50, 614–619. [CrossRef] [PubMed]

48. Zamek-Gliszczynski, M.J.; Taub, M.E.; Chothe, P.P.; Chu, X.; Giacomini, K.M.; Kim, R.B.; Ray, A.S.; Stocker, S.L.; Unadkat, J.D.; Wittwer, M.B.; et al. Transporters in drug development: 2018 itc recommendations for transporters of emerging clinical importance. Clin. Pharmacol. Ther. 2018, 104, 890–899. [CrossRef]

49. Lemmers, V.J.; van den Heuvel, J.J.; Russel, F.G.; Aarnoutse, R.E.; Burger, D.M.; Brüggemann, R.J.; Koenderink, J.B. Inhibitory potential of antifungal drugs on ATP-binding cassette transporters p-glycoprotein, mrp1 to mrp5, bcrp, and bsep. Antimicrob. Agents Chemother. 2016, 60, 3372–3379. [CrossRef]

50. Haenisch, S.; May, K.; Wegner, D.; Caliebe, A.; Cascorbi, I.; Siegmund, W. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of abcc2 and on bioavailability of talinolol. Pharmacogenet. Genom. 2008, 18, 357–365. [CrossRef]

51. Itoda, M.; Saito, Y.; Soyama, A.; Saeki, M.; Murayama, N.; Ishida, S.; Sai, K.; Nagano, M.; Suzuki, H.; Sugiyama, Y.; et al. Polymorphisms in the abcc2 (cmoat/mrp2) gene found in 72 established cell lines derived from japanese individuals: An association between single nucleotide polymorphisms in the 5'-untranslated region and exon 28. Drug Metab. Dispos. 2002, 30, 363–364. [CrossRef]

52. Liu, Y.; Yin, Y.; Sheng, Q.; Lu, X.; Wang, F.; Lin, Z.; Tian, H.; Xu, A.; Zhang, J. Association of abcc2 -24c>t polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS ONE 2014, 9, e82681. [CrossRef] [PubMed]

53. Meyer zu Schwabedissen, H.E.; Kroemer, H.K. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (bcrp/mxr/abcp/abcg2). In Drug Transporters; Handbook of Experimental Pharmacology; Springer: Berlin/Heidelberg, Germany, 2011; pp. 325–371.

54. Allen, J.D.; Schinkel, A.H. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (bcrp/abcg2). Mol. Cancer Ther. 2002, 1, 427–434.

55. Gupta, A.; Unadkat, J.D.; Mao, Q. Interactions of azole antifungal agents with the human breast cancer resistance protein (bcrp). J. Pharm. Sci. 2007, 96, 3226–3235. [CrossRef]

56. Zhang, W.; Sun, S.; Zhang, W.; Shi, Z. Polymorphisms of abcg2 and its effect on voriconazole plasma concentration in immunocompromised children. Clin. Pharmacol. Ther. 2009, 86, 463–468. [CrossRef]

57. Meyer zu Schwabedissen, H.E.; Kim, R.B. Hepatic oatp1b transporters and nuclear receptors pXR and CAR: Interplay, regulation of hepatic metabolism of the metamizole metabolite 4-methylaminoantipyrine. Child Adolesc. Psychiatr. Clin. N. Am. 2009, 6, 1644–1661. [CrossRef] [PubMed]

58. Flockhart, D.A.; Oesterheld, J.R. Cytochrome p450-mediated drug interactions. Child Adolesc. Psychiatr. Clin. N. Am. 2000, 9, 43–76. [CrossRef]

59. Bergogne-Bérézin, É. Clinical role of protein binding of quinolones. Clin. Pharmacokinet. 2002, 41, 741–750. [CrossRef]

60. UCB-Pharma SA. Keppra® Summary of Product Characteristics. Available online: https://www.ema.europa.eu/en/documents/product-information/keppra-epar-product-information_en.pdf (accessed on 22 April 2022).

61. Nicolas, J.M.; Collart, P.; Gerin, B.; Mather, G.; Trager, W.; Levy, R.; Roba, J. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab. Dispos. 1999, 27, 250–254.

62. Hole, K.; Wollmann, B.M.; Nguyen, C.; Haslerno, T.; Molden, E. Comparison of cyp3a4-inducing capacity of enzyme-inducing antiepileptic drugs using 4β-hydroxycholesterol as biomarker. Ther. Drug Monit. 2018, 40, 463–468. [CrossRef]

63. Patsalos, P.N. Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet. 2004, 43, 707–724. [CrossRef]

64. Strolin Benedetti, M.; Whomesley, R.; Nicolas, J.M.; Young, C.; Baltes, E. Pharmacokinetics and metabolism of 14c-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur. J. Clin. Pharmacol. 2003, 59, 621–630. [CrossRef]

65. Li, Z.R.; Wang, C.Y.; Zhou, X.; Jiao, Z. Population pharmacokinetics of levetiracetam: A systematic review. Clin. Pharmacokinet. 2021, 60, 305–318. [CrossRef]